Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Equity · Q4 FY2025 · quarter ended Dec 2025
Total equity rises 75.4% from a year ago
Total equity stood at $30.16M at the end of Q4 FY2025, up 75.4% from a year earlier. Over 3 fiscal years it compounded at +33.9% a year.
Context
- Total equity amounted to 99.7% of total assets at the end of Q4 FY2025, up 8.9 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +75.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 30.16M USD
- Year-over-year change
- +75.4%
- 4-year CAGR
- +85.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.16M | +75.4% |
| FY2024 | 2024-12-31 | 17.19M | +16.0% |
| FY2023 | 2023-12-31 | 14.82M | +18.1% |
| FY2022 | 2022-12-31 | 12.55M | +394.8% |
| FY2021 | 2021-12-31 | 2.54M | — |
Total Equity vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +75.4% is the 2nd highest of 10, against a peer median of -1.2%.
- Total equity amounts to 99.7% of total assets for NNNN, versus a peer median of 70.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$1.09B CAD | -1.2% | -6.0% | 82.7% | |
| Mar 2026 | $782.1M USD | -6.8% | -15.5% | 74.5% | |
| Mar 2026 | $399.9M USD | +2053.8% | — | 79.2% | |
| Mar 2026 | $326.69M USD | +67.1% | — | 61.4% | |
| Feb 2026 | $173.36M USD | -6.7% | -24.5% | 66.5% | |
| Mar 2026 | $113.06M USD | -0.3% | -2.8% | 83.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $30.16M USD | +75.4% | +33.9% | 99.7% |
| Mar 2026 | $18.84M USD | -5.7% | -8.8% | 20.2% | |
| Dec 2025 | -$2.71M USD | — | — | 0.8% | |
| Mar 2026 | -$161.48M USD | -2483.7% | — | 125.3% | |
| Mar 2026 | -$965M USD | +27.4% | — | 7.3% | |
| Peer median (excluding NNNN) | — | -1.2% | -8.8% | 70.5% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.